Study of resistance to alkylating chemotherapy in endocrine tumors
Part of Cancer, Hormones & metabolism clinical trials.
This study looks at why some endocrine tumors (tumors in hormone-making glands) stop responding to a specific type of chemotherapy called alkylating agents. Researchers will collect tissue samples to understand how the tumor changes and why the medicine stops working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You have a tumor in a hormone-making gland (like the pancreas, thyroid, or adrenal gland) that has been confirmed by a biopsy.
- You are about to start treatment with a type of chemotherapy called an alkylating agent, or you have already taken one and the disease came back or keeps growing.
- You do not have a bleeding disorder or take blood thinners that cannot be safely paused for a biopsy.
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and analyzes molecular (cell/DNA-level) information from endocrine tumors or pre-cancer conditions. It may help doctors better understand these tumors and improve diagnosis and treatment planning when you need surgery or a biopsy.
This study looks at neuroendocrine tumors by collecting tissue (when available) and tracking how the disease behaves over time. It may help researchers better understand these cancers, including rare cases of adrenocortical cancer.
This study looks at why some breast cancers stop responding to treatment. It involves taking a small sample of your tumor (biopsy) and blood to understand resistance. If you have HER2-positive or triple-negative breast cancer that is growing despite treatment, you may be able to join.
This study looks at why some lung cancers with an ALK gene change do not respond to ALK-targeted drugs. It may help find better treatments for patients whose cancer stops responding early.
This trial tests a new drug, LBL-024, combined with standard chemotherapy (etoposide and platinum) for people with advanced neuroendocrine carcinoma. The goal is to see if this combination works better than chemo alone.
This trial looks at epigenomic markers in different types of neuroendocrine tumors and cancers to find better ways to diagnose and treat them. It may help if you have a neuroendocrine tumor or certain other gastrointestinal cancers that can be surgically removed or biopsied.
Hear when a new Neuroendocrine (NE) Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.